MedPath

Caprock Mining Corp

Caprock Mining Corp logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
Public
Established
2005-01-01
Employees
102
Market Cap
$155.6M
Website
http://www.capricor.com
Introduction

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Clinical Trials
Related News

Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE)

Phase 2
Completed
Conditions
Duchenne Muscular Dystrophy
Interventions
Biological: Allogeneic Cardiosphere-Derived Cells (CAP-1002)
First Posted Date
2024-03-12
Last Posted Date
2024-04-24
Lead Sponsor
Capricor Inc.
Target Recruit Count
8
Registration Number
NCT06304064
Locations
πŸ‡ΊπŸ‡Έ

University of Florida, Gainesville, Florida, United States

πŸ‡ΊπŸ‡Έ

Cincinnati Children's Medical Center, Cincinnati, Ohio, United States

A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Phase 3
Active, not recruiting
Conditions
Muscular Dystrophies
Neuromuscular Diseases
Muscular Disorders, Atrophic
Muscular Diseases
Nervous System Diseases
Muscular Dystrophy, Duchenne
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Interventions
Biological: Deramiocel (CAP-1002)
Biological: Placebo
Biological: CAP-1002
First Posted Date
2021-11-19
Last Posted Date
2025-06-13
Lead Sponsor
Capricor Inc.
Target Recruit Count
104
Registration Number
NCT05126758
Locations
πŸ‡ΊπŸ‡Έ

Phoenix Children's Hospital, Phoenix, Arizona, United States

πŸ‡ΊπŸ‡Έ

Arkansas Children's Hospital, Little Rock, Arkansas, United States

πŸ‡ΊπŸ‡Έ

UCSD Altman Clinical and Translational Research Institute, La Jolla, California, United States

and more 17 locations

Intravenous Infusion of CAP-1002 in Patients With COVID-19

Phase 2
Completed
Conditions
Covid19
Interventions
Biological: Placebo
Biological: CAP-1002
First Posted Date
2020-11-10
Last Posted Date
2025-02-20
Lead Sponsor
Capricor Inc.
Target Recruit Count
55
Registration Number
NCT04623671
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

University of California Davis, Sacramento, California, United States

πŸ‡ΊπŸ‡Έ

Henry Ford Health System, Detroit, Michigan, United States

and more 1 locations

Open-label Extension of the HOPE-2 Trial

Phase 2
Active, not recruiting
Conditions
Duchenne Muscular Dystrophy
Interventions
Biological: Deramiocel (CAP-1002)
First Posted Date
2020-06-11
Last Posted Date
2025-07-03
Lead Sponsor
Capricor Inc.
Target Recruit Count
13
Registration Number
NCT04428476
Locations
πŸ‡ΊπŸ‡Έ

University of California, Davis, Sacramento, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Colorado, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

Washington University, Saint Louis, Missouri, United States

and more 2 locations

CAP-1002 in Severe COVID-19 Disease

Conditions
COVID-19
First Posted Date
2020-04-08
Last Posted Date
2020-12-01
Lead Sponsor
Capricor Inc.
Registration Number
NCT04338347
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

Phase 2
Completed
Conditions
Muscular Dystrophies
Genetic Diseases, Inborn
Muscular Diseases
Nervous System Diseases
Genetic Diseases, X-Linked
Muscular Dystrophy, Duchenne
Neuromuscular Diseases
Muscular Disorders, Atrophic
Interventions
Drug: Placebo
First Posted Date
2018-01-23
Last Posted Date
2025-05-28
Lead Sponsor
Capricor Inc.
Target Recruit Count
20
Registration Number
NCT03406780
Locations
πŸ‡ΊπŸ‡Έ

University of California, Davis, Sacramento, California, United States

πŸ‡ΊπŸ‡Έ

Children's Hospital Colorado, Aurora, Colorado, United States

πŸ‡ΊπŸ‡Έ

Nemours Children's Hospital, Orlando, Florida, United States

and more 6 locations

Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment

Phase 1
Completed
Conditions
Heart Failure
Renal Insufficiency
Interventions
Drug: Placebo
First Posted Date
2015-11-13
Last Posted Date
2020-02-11
Lead Sponsor
Capricor Inc.
Target Recruit Count
8
Registration Number
NCT02603614
Locations
πŸ‡ΊπŸ‡Έ

Orange County Research Center, Tustin, California, United States

HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne)

Phase 2
Completed
Conditions
Duchenne Muscular Dystrophy
Cardiomyopathy
Interventions
Drug: Allogeneic Cardiosphere-Derived Cells (CAP-1002)
First Posted Date
2015-06-30
Last Posted Date
2025-01-09
Lead Sponsor
Capricor Inc.
Target Recruit Count
25
Registration Number
NCT02485938
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

πŸ‡ΊπŸ‡Έ

University of Florida, Gainesville, Florida, United States

πŸ‡ΊπŸ‡Έ

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Safety Study of Cenderitide in Stable Chronic Heart Failure

Phase 2
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2015-02-09
Last Posted Date
2020-02-11
Lead Sponsor
Capricor Inc.
Target Recruit Count
14
Registration Number
NCT02359227
Locations
πŸ‡ΊπŸ‡Έ

Orange County Research Center, Tustin, California, United States

Dilated cardiomYopathy iNtervention With Allogeneic MyocardIally-regenerative Cells (DYNAMIC)

Phase 1
Conditions
Nonischemic Cardiomyopathy
Ischemic Cardiomyopathy
Heart Failure
Dilated Cardiomyopathy (DCM)
Interventions
Biological: Allogeneic Cardiosphere-Derived Cells (CDCs)
First Posted Date
2014-11-18
Last Posted Date
2016-06-21
Lead Sponsor
Capricor Inc.
Target Recruit Count
42
Registration Number
NCT02293603
Locations
πŸ‡ΊπŸ‡Έ

Cedars-Sinai Medical Center, Los Angeles, California, United States

Β© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy